Mahtab Sohrevardi, MD
Endocrinology, Diabetes & Metabolism Physician · Pasadena, CA
Mahtab Sohrevardi, MD is an endocrinology, diabetes & metabolism physician with a practice address in Pasadena, California, and NPI 1578777033, issued on May 10, 2007. Check the license (California C149677, as entered in NPPES) on the Medical Board of California; the Medicare figures below come from public CMS files.
- Name
- Mahtab Sohrevardi
- Credential
- MD
- Primary taxonomy
- Endocrinology, Diabetes & Metabolism Physician 207RE0101X
- License numbers
- C149677 CA
5400601-1205 UT
Self-reported in NPPES; status is on the state search - Practice location
- 55 E California Blvd Ste 204, Pasadena, CA 91105
- Phone
- (626) 397-8323
- Enumerated
- May 10, 2007
- Record last updated
- Mar 7, 2023
- Fax
- (626) 792-3611
- Medicare enrollment
- Enrolled (PECOS I20190702002081); accepts Medicare assignment
- Telehealth
- Offers telehealth (CMS)
- Entity
- Type 1 · individual
Also registered at 55 E California Blvd Ste 204
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Anna Newby, M.S., R.D., L.D.Registered Dietitian1245470152
- Cedric Ng, M.D.Pediatric Endocrinology Physician1437446952
- Yang Shen, M.D.Endocrinology, Diabetes & Metabolism Physician1609189075
- Darice Yang, M.D.Rheumatology Physician1427255454
Verify Mahtab Sohrevardi in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersMedical Board of California
Search for license C149677Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
83% more Medicare Part D claims than the average endocrinology, diabetes & metabolism physician in 2024
4,814 Medicare Part D claims for 506 beneficiaries, against an average of 2,630 among the 8,223 providers of this specialty who prescribed in Part D. Brand-name drugs were 49% of claims.
Most prescribed
- Levothyroxine Sodium534 claims
- Trulicity340 claims
- Mounjaro233 claims
- Ozempic233 claims
- Jardiance202 claims
- Atorvastatin Calcium179 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
The practice group's MIPS final score for 2023 (Medicare payment program): 80.5 of 100
The Merit-based Incentive Payment System score is reported for the practice group, not for one clinician alone. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.
Source: CMS Quality Payment Program, MIPS performance year 2023, group reporting; category weights for 2023 (qpp.cms.gov).
Industry payments in 2024: $1,366.00
49 payments; by number, the most common kind was food and beverage; the largest payer was Medtronic, Inc. The 5,661 providers of this specialty with any payment received $5,742.15 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Bills Medicare through 2 group practices
- Cedars-Sinai Medical Care FoundationPasadena, CA
- The Huntington Medical FoundationPasadena, CA
Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).
Endocrinology, Diabetes & Metabolism Physician providers in California
There are 1,131 endocrinology, diabetes & metabolism physician records in California.
Other endocrinology, diabetes & metabolism physician records in California
- Evan Abel, MDSanta Monica, CA1619067238
- Anita Abraham, M.D.Stockton, CA1558380337
- Sallie Adams, M.D.Roseville, CA1255342085
- Helen Adelberg, M.D.Encino, CA1093935447
- Yewande Adepoju, DOOroville, CA1467892984
- David Aftergood, MDBeverly Hills, CA1639259328
- Nidhi Agarwal, MDTorrance, CA1518387125
- Bahar Aghighi, MDSanta Cruz, CA1770562134
- Tyler Aguinaldo, MDBurlingame, CA1306811906
- Susan Ahern, D.O.Ventura, CA1508156597
Common questions
What is Mahtab Sohrevardi, MD's NPI number?
Mahtab Sohrevardi, MD's National Provider Identifier (NPI) is 1578777033, issued on May 10, 2007. An NPI identifies a provider in billing; it is not a license.
Where is Mahtab Sohrevardi, MD located?
The NPPES record lists a practice address at 55 E California Blvd Ste 204, Pasadena, CA, 91105. Phone: (626) 397-8323. Providers update this record themselves, so call before visiting.
How can I verify Mahtab Sohrevardi, MD's license?
NPPES lists California license number C149677, as entered by the provider. Search the Medical Board of California at https://www.mbc.ca.gov/License-Verification/default.aspx. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Mahtab Sohrevardi, MD prescribe under Medicare Part D?
In 2024, Mahtab Sohrevardi, MD had 4,814 Medicare Part D claims for 506 beneficiaries; the average among endocrinology, diabetes & metabolism physician prescribers was 2,630. Part D covers Medicare prescriptions only.
What is Mahtab Sohrevardi, MD's MIPS final score?
The 2023 MIPS final score is 80.5 of 100, reported for the practice group. The average among 454,083 clinicians with a measured score was 83.5.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.